GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Curanex Pharmaceuticals CURX · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.20

-0.16%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2022FY2025

Net income

−$4.2m

FY2022FY2025

Free cash flow

−$10.5m

FY2022FY2025

Shareholders' equity

$11.2m

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue———$26,000
Gross profit———$4,429
Research and development$3.0m———
Operating income−$4.2m−$365,062−$19,298−$20,233
Net income−$4.2m−$361,506−$19,198−$20,233
Diluted earnings per share-2.98-0.26-0.01-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets$11.6m$517,935$74,366$10,232
Cash and short-term investments$5.0m$148,891$74,366—
Total liabilities$361,040$14,575$14,276—
Debt$346,699———
Shareholders' equity$11.2m$503,360$60,090$10,232
Shares outstanding1m1m1m1m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−$10.5m−$555,575−$120$3,336
Capital spending—−$5——
Free cash flow−$10.5m−$555,580−$120$3,336

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit—−$35,041−$34,294—−$15,030———
Operating income−$3.3m−$3.2m−$3.1m−$951,327−$57,255−$137,452−$138,591−$102,070
Net income−$3.3m−$3.2m−$3.1m−$954,059−$60,346−$137,583−$137,163−$99,942
Diluted earnings per share-2.32-2.22-2.17-0.67-0.04-0.10-0.10-0.07
Cash from operations−$1.0m——−$9.0m————
Total assets$5.1m$8.4m$11.6m$14.5m$787,174$786,940$517,935$646,122
Cash and short-term investments$2.9m$4.0m$5.0m$5.8m$108,862$198,943$148,891$244,320
Debt$94,411$107,090$122,689$61,150$470,636$262,618——
Shareholders' equity$4.8m$8.1m$11.2m$14.3m$305,431$365,777$503,360$640,523

Growth per year

Compound annual rate

3 years5 years10 years
Operating income493.9%——
Net income493.3%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-2.2

Share price return

Finished calendar years

2025
Return-41%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 20 Aug 2026

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.